Matchpoint Therapeutics Announces $150 Million Series B Financing
FROM THE WIRE · FINANCE.YAHOO.COM
Matchpoint Therapeutics Financing co-led by Nextech Invest and Norwest, with participation from new and existing investors Proceeds to support clinical development of MPT-062, an oral first-in-class T cell modulator, to begin in 2027 WATERTOWN, Mass., Oct. 07, 2026 (GLOBE…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishA Series B financing for a biotech company is sector-relevant but not a major market-moving event.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Matchpoint Therapeutics closed a $150 million Series B financing round.
- 02The financing was co-led by Nextech Invest and Norwest, with participation from BB Biotech and other investors.
- 03Proceeds will support clinical development of MPT-062, an oral first-in-class T cell modulator.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
BB Biotech AG52.72 EURMarket closedtoday -0.56%Positive BB Biotech AG49.30 CHF+0.20%today -0.70%Positive
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets